Government programs are growing increasingly complicated and risky for any pharmaceutical manufacturer, especially with the changes proposed in Healthcare Reform from the Obama Administration. Beginning Q1 2010, every manufacturer’s pricing methodologies and calculations will significantly be impacted due to the adoption of the proposed legislation. IIR’s GP Summit provides a clear guide to the new pricing methodologies and an understanding of how your reimbursement strategies should change to protect your bottom line. As regulations change, it is imperative to have correct systems, procedures and documentation in place to provide the government with accurate data to avoid the investigations that could lead to multimillion dollar settlements. Failure to report correctly will have a profound effect on many other programs, impacting the reimbursement of products and potential losses in fines and penalties. Gain comprehensive clarification on compliant management of GP, hearing directly from the Government on their processes and expectations. Don’t miss special track to decipher how chargebacks affect Government pricing calculations and ultimately the company’s bottom line. Enhance the effective management and administration of each government program with a special focus on correct pricing calculations and an understanding of the business aspects of GP and its impact on commercial objectives.